Worldwide Research & Collaboration Needed to Combat Covid-19
In light of the coronavirus (COVID-19) outbreak, leading data and analytics company GlobalData has analyzed several of the largest COVID-19 clinical trials in terms of participant size.
Mohamed Abukar, Clinical Trials Analyst at GlobalData, said “GDCT0379047 (ChiCTR2000029573) and GDCT0379500 (ChiCTR2000029602) are the two largest coronavirus trials, with both trials aiming to recruit 600 participants.”
Trial GDCT0379047, an interventional planned Phase 4 trial, tests the efficacy and safety of a recombinant cytokine gene-derived protein injection combined with Umifenovir (Arbidol), Lopinavir/Litonavir. The study aims to combine the immunostimulatory effects of the cytokine gene-derived protein injection with the anti-viral properties of Umifenovir, Lopinavir/Litonavir against COVID-19. This trial is located in Zhejiang, China, and is sponsored by the Zhejiang University School of Medicine Hospital 1 in collaboration with Jiehua Biotechnology (Qingdao) Co.
Trial GDCT0379500, an interventional ongoing Phase 0 study, aims to test the preventative effects of traditional Chinese medicine (TCM) against COVID-19. This study aims to determine if the addition of TCM to standard health education is more effective than health education alone in preventing COVID-19. This trial is located in Hubei, China, and is sponsored by the Hubei Hospital of Traditional Chinese Medicine in collaboration with the State Administration of Traditional Chinese Medicine.
Abukar concludes “Evidently, a substantial research effort has been geared toward therapies utilizing Umifenovir, or TCM with four of the top five clinical trials involving these agents. Nevertheless, to effectively combat the disease a greater level research and collaboration is required worldwide; currently an overwhelming amount of the research is being conducted in China, which may limit the scope of potential therapies being investigated.
“China Evergrande group, a real estate company listed on Fortune Global 500, aims to improve collaborative efforts by awarding a joint $115 million grant to Harvard and Guangzhou Institute of Respiratory Disease, with the principle aim of enhancing diagnostic methods and treatment options of COVID-19 respiratory disease.”
4,000 of the world’s largest companies, including over 70% of FTSE 100 and 60% of Fortune 100 companies, make more timely and better business decisions thanks to GlobalData’s unique data, expert analysis and innovative solutions, all in one platform. GlobalData’s mission is to help our clients decode the future to be more successful and innovative across a range of industries, including the healthcare, consumer, retail, financial, technology and professional services sectors.
To gain access to our latest press releases: GlobalData Media Centre. Analysts available for comment. Please contact the GlobalData Press Office:
EMEA & Americas: +44 (0)207 832 4399
Asia-Pacific: +91 40 6616 6809
Email: pr@globaldata.com
For expert analysis on developments in your industry, please connect with us on:
Total Page Views: 1306
